Abstract
Purpose MRI screening has been shown to allow for an earlier diagnosis of breast cancer in asymptomatic women with proven or suspected mutations in breast cancer susceptibility genes. Major efforts are presently addressed to assess to which extent this improves high-risk women survival. Methods We here discuss the article by Gareth et al (Breast Cancer Res Treat 145(3):663–672, 2014). Results Gareth and colleagues compared MRI sensitivity and specificity and clinical characteristics of breast cancers detected in their study with those reported in six similar prospective cohort screening studies. We here extended this analysis to a total of nine published cohort studies, including the High Breast Cancer Risk Italian Study 1 (HIBCRIT-1) for which we considered the final results published in 2011, instead of those of our interim report (2007) utilized by Gareth et al. Our updated analysis shows that in a total of 392 diagnosed breast cancers, 77 % (95 % confidence interval [CI] 73–81 %) were invasive and 52 % (95 % CI 46–58 %) were invasive grade 3. Only 23 % (95 % CI 18–28 %) of MRI-detected invasive breast cancers had metastatic lymph nodal involvement and 45 % (95 % CI 39–51 %) had a size ≤10 mm. Discussion and Conclusions The capability of MRI to detect invasive breast cancers at early stages could at least partly explain the significantly higher 10-year survival estimated by Gareth et al for asymptomatic highrisk women screened using MRI in the period 1997–2013 (95 %) compared with unscreened high-risk women diagnosed for breast cancer after 1990 and identified as BRCA1/BRCA2 mutation carriers in the years following diagnosis (74 %). It appears however worth noting that the evolution of therapeutic protocols applied to high-risk patients after the discovery of BRCA mutations in 1995-1997 could also have contributed to the observed difference in the survival of these two groups. On the other hand, we agree with Gareth et al that larger datasets are needed to evaluate to which extent improvements in the cancer detection impact on disease-free and overall survival of MRI-screened compared with mammography-alone-screened high-risk women.
References
Gareth ED, Nisha K, Yit L et al (2014) MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat 145:663–672
Sardanelli F, Podo F, D’Agnolo G et al (2007) Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT Study): interim results. Radiology 242:698–715
Sardanelli F, Podo F, Santoro F et al (2011) Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the High Breast Cancer Risk Italian 1 study). Final results. Invest Radiol 46:94–105
Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumors. Nature 406:747–752
Kuhl CK, Schrading S, Leutner CC et al (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469–8476
Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325
Leach MO, Boggis CR, Dixon AK et al (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365:1769–1778
Hagen AI, Kvistad KA, Maehle L et al (2007) Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 16:367–374
Riedl CC, Ponhold L, Flöry D et al (2007) Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 13:6144–6152
Rijnsburger AJ, Obdeijn IM, Kaas R et al (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28:5265–5273
Kuhl CK, Weigel S, Schrading S et al (2010) Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 28:1450–1457
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
This letter to the editor refers to the article available at 10.1007/s10549-014-2931-9, and a rebuttal letter to this letter to the editor is available at 10.1007/s10549-014-3101-9.
Rights and permissions
About this article
Cite this article
Santoro, F., Podo, F. & Sardanelli, F. MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis. Breast Cancer Res Treat 147, 685–687 (2014). https://doi.org/10.1007/s10549-014-3097-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-014-3097-1